Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of ex Vivo Activated and Expanded Autologous Cytokine-induced Killer Cells for Colon Cancer Patients

NCT03329664 is registered in ClinicalTrials.gov with Sabz Biomedicals as lead sponsor.

NCT NCT03329664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03329664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of ex Vivo Activated and Expanded Autologous Cytokine-induced Killer Cells for Colon Cancer Patients
Lead sponsor
Sabz Biomedicals
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 9, 2020
Completion date
January 31, 2022
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer stage iv